This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2010 by University of Wuerzburg.
Recruitment status was:  Recruiting
Information provided by:
University of Wuerzburg Identifier:
First received: October 31, 2007
Last updated: September 23, 2010
Last verified: September 2010
The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year.

Condition Intervention Phase
Acromegaly Heart Failure Hypertrophy, Left Ventricular Drug: pegvisomant Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study

Resource links provided by NLM:

Further study details as provided by University of Wuerzburg:

Primary Outcome Measures:
  • Change in peak systolic strain rate (SRSYS) determined by Color Doppler Myocardial Imaging (CDMI). [ Time Frame: one year ]

Secondary Outcome Measures:
  • Ejection fraction,Enddiastolic thickness of the infero-lateral wall,Diastolic function,Left ventricular mass index,Stroke volume,Ejection fraction (MRI),CO,Late hyperenhancement,IGF-I,insulin sensitivity,Ringsize,adverse events,Endothelial function [ Time Frame: one year ]

Estimated Enrollment: 4
Study Start Date: June 2006
Estimated Study Completion Date: December 2010
Arms Assigned Interventions
patients with active acromegaly and impaired cardiac function
Drug: pegvisomant
booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
Other Name: Somavert


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Active acromegaly in adult subjects (≥ 18 years) after surgery and/or radiation therapy with elevated IGF-1 levels despite treatment with somatostatin analogues or dopamine agonists
  • Pegvisomant therapy is indicated (i. e. patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy, or for whom these therapies are not appropriate)
  • Evidence of left ventricular hypertrophy (infero-lateral wall thickness ≥ 12 mm assessed by echocardiography) or
  • Evidence of impaired diastolic function (≥ stage 2 as assessed by echocardiography) or
  • Evidence of systolic dysfunction (Ejection fraction < 50% assessed by echocardiography)
  • Stable medication for arterial hypertension and heart failure for 3 months
  • Written informed consent.

Exclusion Criteria:

  • Pregnancy and lactation period
  • Previous therapy with Pegvisomant
  • Suspected or known hypersensitivity to the drug or any of its components
  • Contraindications for MRI
  • History of malignancy during the last 5 years
  • Suspected or known drug or alcohol abuse
  • Patients who are neither able to self administer study medication on a daily basis nor have a caregiver who can administer study medication to the patient on a daily basis
  • Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion
  • Participation in another clinical trial
  • Pituitary adenoma with a distance to the optic chiasm of < 3 mm
  • Any other drug for treatment of acromegaly (e.g. dopamine agonists, Somatostatin analogues) which would be necessary during the study or patients who apply for radiotherapy
  • Instable heart insufficiency classified as NYHA IV.
  • Severe renal insufficiency, liver transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00552851

Contact: Gwendolyn Bender, MD 004993120139716
Contact: Bruno Allolio, MD 004993120139020

University of Wuerzburg, Department of Endocrinology Recruiting
Wuerzburg, Bavaria, Germany, 97080
Contact: Gwendolyn Bender, MD    004993120139716   
Sponsors and Collaborators
University of Wuerzburg
Principal Investigator: Bruno Allolio, MD University of Wuerzburg. Department of Endocrinology
  More Information

Responsible Party: Prof. Bruno Allolio, Department of Endocrinology Identifier: NCT00552851     History of Changes
Other Study ID Numbers: NRA 6290010
EudraCT No: 2006-001108-35
Study First Received: October 31, 2007
Last Updated: September 23, 2010

Keywords provided by University of Wuerzburg:
heart failure

Additional relevant MeSH terms:
Heart Failure
Hypertrophy, Left Ventricular
Heart Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017